Department of Physiology and Biophysics, School of Medicine, Case Western Reserve University , Cleveland, Ohio.
Department of Pathobiology, Lerner Research Institution, Cleveland Clinic , Cleveland, Ohio.
Am J Physiol Endocrinol Metab. 2019 May 1;316(5):E829-E836. doi: 10.1152/ajpendo.00439.2018. Epub 2019 Mar 12.
Obesity is a major risk factor for metabolic disease. Growth differentiation factor 15 (GDF15) has shown promise as a weight loss agent for obesity in animal studies. In healthy lean humans, fasting plasma GDF15 increases after acute exercise. However, the role of GDF15 in human obesity and the response of plasma GDF15 to exercise training in patients with obesity is unknown. Here, 24 sedentary volunteers with obesity [age: 65 ± 1 yr; body mass index (BMI): 35.3 ± 0.9 kg/m] participated in a supervised 12-wk aerobic exercise intervention: 1 h/day, 5 days/wk at ~85% maximum heart rate with controlled isocaloric diet. As a result, plasma GDF15 was significantly increased (PRE: 644.1 ± 42.6 pg/ml, POST: 704.4 ± 47.2 pg/ml, < 0.01) after the exercise intervention. Inconsistent with animal models, ΔGDF15 was not correlated with change in weight, BMI, or resting energy expenditure. However, ΔGDF15 was correlated with a reduction in total fat mass ( < 0.05), abdominal fat mass ( < 0.05), and android fat mass ( ≤ 0.05). Participants with a positive GDF15 response to exercise had increased total fat oxidation (PRE: 0.25 ± 0.05 mg·kg·min, POST: 0.43 ± 0.07 mg·kg·min, ≤ 0.05), metabolic flexibility [PRE: -0.01 ± 0.01 delta respiratory quotient (RQ), POST: 0.06 ± 0.01 delta RQ, < 0.001], and insulin sensitivity (PRE: 0.33 ± 0.01 QUICKI index, POST: 0.34 ± 0.01 QUICKI index, < 0.01), suggesting a link between GDF15 and fat mass loss as well as exercise-induced metabolic improvement in humans with obesity. We conclude that the exercise-induced increase in plasma GDF15 and the association with reduced fat mass may indicate a role for GDF15 as a therapeutic target for human obesity.
肥胖是代谢疾病的一个主要危险因素。生长分化因子 15(GDF15)在动物研究中表现出作为肥胖减肥剂的潜力。在健康的瘦人中,空腹血浆 GDF15 在急性运动后增加。然而,GDF15 在人类肥胖中的作用以及肥胖患者血浆 GDF15 对运动训练的反应尚不清楚。在这里,24 名久坐不动的肥胖志愿者[年龄:65±1 岁;体重指数(BMI):35.3±0.9kg/m]参加了一项监督的 12 周有氧运动干预:每天 1 小时,每周 5 天,在最大心率的~85%左右进行,同时控制热量摄入。结果,运动干预后血浆 GDF15 显著增加(PRE:644.1±42.6pg/ml,POST:704.4±47.2pg/ml, < 0.01)。与动物模型不一致的是,ΔGDF15 与体重、BMI 或静息能量消耗的变化无关。然而,ΔGDF15 与总脂肪量的减少( < 0.05)、腹部脂肪量( < 0.05)和腹型脂肪量( ≤ 0.05)相关。对运动有积极 GDF15 反应的参与者的总脂肪氧化增加(PRE:0.25±0.05mg·kg·min,POST:0.43±0.07mg·kg·min, ≤ 0.05)、代谢灵活性[PRE:-0.01±0.01 呼吸商(RQ)变化,POST:0.06±0.01 RQ 变化, < 0.001]和胰岛素敏感性(PRE:0.33±0.01 QUICKI 指数,POST:0.34±0.01 QUICKI 指数, < 0.01),这表明 GDF15 与脂肪量减少以及肥胖人群运动引起的代谢改善之间存在联系。我们得出结论,运动引起的血浆 GDF15 增加及其与脂肪量减少的相关性可能表明 GDF15 作为人类肥胖的治疗靶点的作用。